Despite the many unknowns, including dose, schedule, patient selection, combination strategies, safety, durability, and even efficacy, therapies based on HSP and PD-1/PD-L1 blockades hold promise for the treatment of patients diagnosed with various hematological malignancies, including MPN. This evidence concerns the gene PDCD1 and myeloproliferative neoplasm.